UFT and oral calcium folinate as first-line chemotherapy for metastatic gastric cancer

ONCOLOGY

Volumn 13, Issue 7 SUPPL., 1999, Pages 61-63

  Ravaud, Alain ^a   Borner, Markus ^b   Schellens, Jan H M ^c   Geoffrois, Lionnel ^d   Schöffski, Patrick ^e   Wanders, Jantien ^f   Hanauske, Axel R ^g,h  

^a INSTITUT BERGONIÉ   (France)

^b UNIVERSITY OF BERN   (Switzerland)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d CENTRE ALEXIS VAUTRIN   (France)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f New Drug Development Office   (Netherlands)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h Center for Hematology and Oncology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINATE CALCIUM; METHOTREXATE; MITOMYCIN C; TEGAFUR; URACIL;

ADULT; AGED; ASTHENIA; BONE MARROW SUPPRESSION; CANCER GRADING; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; MALAISE; MALE; METASTASIS; OUTPATIENT; PALLIATIVE THERAPY; PROGNOSIS; REMISSION; STOMACH CANCER; STOMATITIS; TREATMENT PLANNING;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG THERAPY, COMBINATION; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; MIDDLE AGED; PALLIATIVE CARE; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TEGAFUR; URACIL;

EID: 0032799671     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Boring C, Squires T, Tong J: Cancer Statistics. CA Cancer J Clin 41:28-29, 1991.
2. Mettlin C: Epidemiologic studies in gastric adenocarcinoma, in Douglass HO Jr (ed): Gastric- Cancer, pp 1-25. New York, Churchill Livingstone, 1988.
3. Cocconi G, De Lisi V, Di Blasio B: Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer. Cancer Treat Rep 66:1263-1266, 1982.
4. Cullinan SA, Moertel CG, Fleming TR, et al: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 253:2061-2067, 1985.
5. Moertel CG, Lavin PT: Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 63:1863-1869, 1979.
6. Lacave AJ, Wils J, Diaz-Rubio E, et al: Cisplatinum as second-line chemotherapy in advanced gastric adenocarcinoma. Am J Clin Oncol 6:35-38, 1983.
7. Leichman L, McDonald B, Dindogru A, et al: Cisplatin: An active drug in the treatment of disseminated gastric cancer. Cancer 53:18-22, 1984.
8. MacDonald JS, Schein PS, Wooley PV, et al: 5-Fluorouracil, mitomycin-C, and adriamycin (FAM): A new combination chemotherapy program for advanced gastric carcinoma. Ann Intern Med 93:533-536, 1980.
9. Epelbaum R, Haim N, Stein M, et al: Treatment of advanced gastric cancer with DDP (cisplatin), adriamycin, and 5-fluorouracil (DAF). Oncology 44:201-206, 1987.
10. Lacave AJ, Buesa JM, Gracia JM, et al: Cisplatin and 5-fluorouracil in the treatment of advanced gastric cancer (abstract). EORTC Symp Adv in Gastrointest Tract Cancer Res and Treat 44:1989.
11. Preusser P, Wilke H, Achtermath W, et al: Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7:1310-1317, 1989.
12. Katz A, Gansi R, Simon S, et al: Phase II trial of VP-16, Adriamycin and cisplatinum in patients with advanced gastric cancer (abstract). Proc Am Soc Clin Oncol 8:98, 1989.
13. Taguchi T: Combination chemotherapy with etoposide, Adriamycin, and cisplatin (EAP) for advanced gastric cancer (abstract). Proc Am Soc Clin Oncol 8:108, 1989.
14. Kelsen D, Atiq O, Saltz L, et al: FAMTX (fluorouracil, methotrexate, adriamycin) is as effective and less toxic than EAP (etoposide, Adriamycin, cisplatin): A random assignment trial in gastric cancer (abstract). Proc Am Soc Clin Oncol 10:37, 1991.
15. Wilke H, Preusser P, Fink U, et al: New developments in the treatment of gastric carcinoma. Semin Oncol 17:61-70, 1990.
16. Klein HO : Long-term results with FAMTX (5-fluorouracil, Adriamycin, methotrexate) in advanced gastric cancer. Cancer Res 9:1025-1026, 1989.
17. Wils JA, Klein HO, Wagener DJT, et al: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 9:827-831, 1991.
18. Webb A, Cunningham D, Scarffe JH, et al: A randomized trial comparing ECF with FAMTX in advanced oesophago-gastric cancer (abstract 1462). Proc Am Soc Clin Oncol 15:465, 1996.
19. De Lisi V, Cocconi G, Tonato M, et al: Randomized comparison of 5-FU alone or combined with carmustine, doxorubicin, and mitomycin (BAFM) in the treatment of advanced gastric cancer. A phase III trial of the Italian Clinical Research Oncology Group (GOIRC). Cancer Treat Rep 70:481-485, 1986.
20. Beretta G, Anoldi E, Beretta GD, et al: Fluorouracil vs FAM polychemotherapy in gastric cancer: A randomized study. Proc ECCO V. P-706, 1989.
21. Fujii S, Kitano S, Ikenaka K, et al: Studies of co-administration of uracil or cytosine on anti- tumor activity of FT-207 or 5-FU derivatives. Jpn J Cancer Chemother 6:377-384, 1979.
22. Hanauske AR: UFT in gastric cancer: Current status and further developments. Oncology 11(suppl 10): 113-118, 1997.
23. Takiuchi H, Ajani JA: Uracil-tegafur in gastric carcinoma: A comprehensive review. J Clin Oncol 16::2877-2885, 1998.